SWOG 1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

December 10, 2018
https://clinicaltrials.gov/ct2/show/NCT03698019
Cancer - Melanoma
Principal Investigator: Ding Wang, MD
CANCER, MELANOMA, HIGH RISK
In Progress